Cargando…
900. Switching to DTG/3TC Fixed-Dose Combination (FDC) Is Non-inferior to Continuing a TAF-Based Regimen (TBR) in Maintaining Virologic Suppression Through 144 Weeks (TANGO Study)
BACKGROUND: DTG/3TC is a complete 2-drug regimen (2DR) for the treatment of HIV-1 infection. Non-inferior virologic efficacy has been proven over 3 years in treatment-naive people living with HIV (PLWH) and 2 years in a stable switch setting. METHODS: TANGO, a randomized, open-label, non-inferiority...
Autores principales: | Osiyemi, Olayemi, Ajana, Faïza, Bisshop, Fiona, De Wit, Stéphane, Portilla, Joaquín, Routy, Jean-Pierre, Wyen, Christoph, Ait-Khaled, Mounir, Pappa, Keith, Wang, Ruolan, Leone, Peter, Wright, Jonathan, Wynne, Brian, van Wyk, Jean A, Aboud, Michael, Smith, Kimberly |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644729/ http://dx.doi.org/10.1093/ofid/ofab466.1095 |
Ejemplares similares
-
MUDANÇA PARA DTG/3TC EM COMBINAÇÃO DE DOSE FIXA FOI NÃO‐INFERIOR À CONTINUIDADE DE ESQUEMA BASEADO EM TAF (TBR) NA MANUTENÇÃO DA SUPRESSÃO VIRAL POR 96 SEMANAS (ESTUDO TANGO)
por: Wyk, Jean Van, et al.
Publicado: (2021) -
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial( )
por: Osiyemi, Olayemi, et al.
Publicado: (2022) -
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
por: van Wyk, Jean, et al.
Publicado: (2020) -
69. Incidence of metabolic complications among treatment-naïve adults living with HIV-1 randomized to B/F/TAF, DTG/ABC/3TC or DTG+F/TAF after 144 Weeks
por: Daar, Eric, et al.
Publicado: (2021) -
1284. Suppressed Switch to DTG/3TC 2-Drug Regimen Vs. BIC- or DTG-Based 3-Drug Regimens
por: Pierone, Gerald, et al.
Publicado: (2022)